Risk scores are statistical indicators based on prescribing patterns compared to specialty peers. They are NOT allegations of fraud, misconduct, or improper care. Many legitimate medical reasons can explain outlier prescribing.
Read our methodology →Risk Flags
Risk indicators are statistical patterns, not allegations. Learn more
7,199
Total Claims
$769K
Drug Cost
949
Beneficiaries
$810
Cost/Patient
Risk Score Breakdown 21/100
Score components are additive. Read full methodology
Peer Comparison vs. 2,621 Pain Management providers
+56%
Opioid rate vs peers
64.2% vs 41.3% avg
+103%
Cost per patient vs peers
$810 vs $399 avg
+142%
Brand preference vs peers
9.1% vs 3.8% avg
⚠️ Opioid + Benzodiazepine Co-Prescriber
This provider prescribes both opioids and benzodiazepines. The FDA has issued a Black Box Warning about the life-threatening risks of concurrent use.
🔎 Data Overview
This provider co-prescribes opioids and benzodiazepines — a combination carrying an FDA Black Box Warning due to increased risk of respiratory depression and death. While sometimes clinically necessary, this combination requires careful justification.
Insights generated from CMS data analysis. Statistical patterns are not accusations — always consider clinical context.
Opioid Prescribing
64.2%
Opioid Rate
4,620
Opioid Claims
$435K
Opioid Cost
18.6%
Long-Acting Rate
This provider's opioid prescribing rate of 64.2% is above the 20% threshold that CMS considers elevated.
Brand vs Generic
Brand: 655 claims · $515K
Generic: 6,544 claims · $254K
Top Prescribed Drugs
| Drug (Generic) | Claims | Cost |
|---|---|---|
| Buprenorphine Hcl | 81 | $81K |
| Oxycodone Myristate | 89 | $74K |
| Rimegepant Sulfate | 33 | $67K |
| Onabotulinumtoxina | 49 | $66K |
| Hydrocodone/Acetaminophen | 1,327 | $43K |
| Oxycodone Hcl | 1,179 | $39K |
| Buprenorphine | 121 | $38K |
| Oxycodone Hcl/Acetaminophen | 877 | $36K |
| Tapentadol Hcl | 14 | $33K |
| Oxycodone Hcl | 43 | $26K |
| Linaclotide | 21 | $16K |
| Naloxegol Oxalate | 36 | $16K |
| Morphine Sulfate | 322 | $15K |
| Pregabalin | 242 | $13K |
| Fremanezumab-Vfrm | 17 | $13K |
Prescribing Profile
52
Unique Drugs
21.0
Anomaly Score
Patient Profile
65
Avg Age
60%
Female
1.60
Avg Risk Score
Explore More
Data from CMS Medicare Part D Prescriber Public Use File, 2023. Risk scores are statistical indicators, not allegations.Methodology · About